Latest California Healthline Stories
HSAs’ Benefits Reward Wealthier Consumers Most
Expanding health savings accounts is favored by President-elect Donald Trump and many GOP lawmakers as they contemplate ways to replace the health law.
Health Law’s Test Kitchen For Payment Reforms Could Offer Tool For GOP Ideas
The Centers for Medicare & Medicaid Innovation was charged by the health law with exploring payment reforms that could cut health care costs and possibly improve quality. But its future is hinged to whether GOP lawmakers see value in its work.
Enfermos… ¿y en bancarrota? Consumidores gastarán más en drogas en 2017
En 2017, muchos más planes de salud en los mercados de seguros requerirán que los consumidores paguen una sustancial parte del costo de los medicamentos más caros, dicen, para disuadir a pacientes muy enfermos de elegir sus planes.
Children’s Hospital Partnership Boosts Care For Sick Kids
An innovative partnership in which a children’s hospital shares revenue and costs with a community hospital helps improve access to specialized care.
FDA’s Drug Approval Team Copes With 700 Unfilled Jobs As Industry Lures Staff
The FDA’s drug-approval team is short more than 700 people and losing skilled staff members to the drug industry.
Are Blues’ Plans Benefiting Unfairly From Program To Offset Cost Of Sicker Patients?
Other insurers complain that Blue Cross Blue Shield plans have bloated overhead costs and reap too much from the Obamacare risk-adjustment fund, paid for by insurers. The companies deny it.
Hospitals Say They’re Being Slammed By Drug Price Hikes
In a report out tuesday, hospital groups said drug prices have skyrocketed since 2013, triggering a huge increase in what hospitals spend on pharmaceuticals.
Poll Finds Majority Of Americans Want Restraints On Drug Prices
As the spiraling costs attract headlines, many people are looking to the government to rein in prescription drug prices, according to the Kaiser Family Foundation poll.
It’s Not Just For Kids: Medicare EpiPen Spending Up 1,100 Percent
The number of prescriptions for Medicare beneficiaries is on the rise, too.
Study Says Concerns About Orphan Drug Spending Are Unjustified
A study in Health Affairs concludes that orphan drugs for rare diseases are not having a widespread or deep impact on health care spending.